0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [Yusimry]
- RxCUI
- 2640395
- RxNorm name
- 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [Yusimry]
- Display name
- 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [Yusimry]
- Full name
- 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [Yusimry]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:21
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761216 | Yusimry | adalimumab-aqvh | 351(k) Biosimilar | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| YUSIMRY | ADALIMUMAB-AQVH | Meitheal Pharmaceuticals Inc. | 4cab600d-6950-409f-a6d8-d447da22cd95 | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | 2640395 |
| YUSIMRY | ADALIMUMAB-AQVH | Coherus BioSciences Inc | cd0e7af2-7704-49ce-bde9-f645294b6788 | 2025-05-16 | Boxed warning, Warnings, Adverse reactions | 2640395 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 4cab600d-6950-409f-a6d8-d447da22cd95 | 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [Yusimry] | SBD | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20251031 |
| 4cab600d-6950-409f-a6d8-d447da22cd95 | Yusimry 40 MG per 0.8 ML Prefilled Syringe | SY | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20251031 |
| 4cab600d-6950-409f-a6d8-d447da22cd95 | 0.8 ML Yusimry 50 MG/ML Prefilled Syringe | SY | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20251031 |
| 4cab600d-6950-409f-a6d8-d447da22cd95 | YUSIMRY 40 MG in 0.8 ML Prefilled Syringe | PSN | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20251031 |
| cd0e7af2-7704-49ce-bde9-f645294b6788 | 0.8 ML adalimumab-aqvh 50 MG/ML Prefilled Syringe [Yusimry] | SBD | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20250516 |
| cd0e7af2-7704-49ce-bde9-f645294b6788 | YUSIMRY 40 MG in 0.8 ML Prefilled Syringe | PSN | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20250516 |
| cd0e7af2-7704-49ce-bde9-f645294b6788 | 0.8 ML Yusimry 50 MG/ML Prefilled Syringe | SY | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20250516 |
| cd0e7af2-7704-49ce-bde9-f645294b6788 | Yusimry 40 MG per 0.8 ML Prefilled Syringe | SY | 6 | These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | 20250516 |